Clinical Trial Update: Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

View source ↗

Summary

Expanded access program for venetoclax and navitoclax in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma is no longer avail…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma

Drugs mentioned

• Navitoclax (navitoclax)
• Venclexta (venetoclax)

Snippet

Sponsor: Kathleen Ludwig | Conditions: Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma | Status: NO_LONGER_AVAILABLE